HONG
KONG, Aug. 16, 2022 /PRNewswire/ -- Global
Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, today announced that
the Company filed its Annual Report on Form 20-F with the U.S.
Securities and Exchange Commission. The filed Form 20-F includes
audited financial statements for the fiscal year ended March 31, 2022. The Form 20-F can be accessed by
visiting the U.S. Securities and Exchange Commission's website at
http://www.sec.gov and also be found at the Investor Relations
section of GCBC's website at http://ir.globalcordbloodcorp.com.
About Global Cord Blood Corporation
Global Cord Blood Corporation is an umbilical cord blood banking
operator serving multiple regions in China. Global Cord Blood Corporation provides
cord blood collection, laboratory testing, hematopoietic stem cell
processing and stem cell storage services. For more information,
please visit the Company's website at:
http://www.globalcordbloodcorp.com.
View original
content:https://www.prnewswire.com/news-releases/global-cord-blood-corporation-files-annual-report-on-form-20-f-301606629.html
SOURCE Global Cord Blood Corporation